N0577: Phase III Intergroup Study of Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma (CODEL)
Principal Investigator
Study Number
STUDY02001522
Summary
This research study is for people who are newly diagnosed with/or have not been treated with radiation or chemotherapy for, an anaplastic glioma or low grade glioma, a type of brain tumor that has a specific tumor marker type, called the 1p/19q co-deletion. The study is to determine if patients treated with radiation and chemotherapy at the same time followed by chemotherapy alone have a better progression free survival then patients treated with radiation alone followed by chemotherapy. Patients will be asked to have a piece of their tumor that was taken during a prior surgery be tested to confirm the tumor type. Patients will be on treatment for up to 14 weeks and then followed by the study team every 12 weeks for 1 year, then every 4 months for 2 years and then every 6 months until the study closes.
Phase
III
Contact
Available at the following location(s)
- Lebanon
View more details at ClinicalTrials.gov
Do you need help with some of the labels on this page?
Read our glossary of terms